Loading
PT
Poseida Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Aug 2022.
Poseida Therapeutics, Inc.: what insiders have been doing
Poseida Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Poseida Therapeutics, Inc. has had no insider filing for more than a year; the last one goes back to 10 January 2025.
The full history, which starts in 2021, counts 9 purchases against 9 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
83
Thresholds
n/a
Buy Volume
€8M
9 ops. · all time
Sell Volume
€1M
9 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$55.7M
Net income-US$106.3M-190.8% margin
Last declaration on 10 January 2025
Declarations83 total
11,835,673 sharesCOMMON STOCKSEC:0001104659-25-002540:0
58,950 sharesCommon StockSEC:0001415889-25-001089:0
58,950 sharesCommon StockSEC:0001415889-25-001090:0
68,950 sharesCommon StockSEC:0001415889-25-001087:0
58,950 sharesCommon StockSEC:0001415889-25-001086:0
185,000 sharesCommon StockSEC:0001415889-25-001083:0
636,726 sharesCommon StockSEC:0001415889-25-001081:0
223,640 sharesCommon StockSEC:0001415889-25-001082:0
615,836 sharesCommon StockSEC:0001415889-25-001080:0
58,950 sharesCommon StockSEC:0001415889-25-001088:0
254,852 sharesCommon StockSEC:0001415889-25-001084:0
78,600 sharesCommon StockSEC:0001415889-25-001085:0
23,313 shares@ US$9.6025.2% of flowCommon StockSEC:0000950170-25-001527:0
30,000 shares@ US$2.7819.2% of flowCommon StockSEC:0000950170-24-135466:0
30,000 shares@ US$2.7819.3% of flowCommon StockSEC:0000950170-24-131665:0
19,650 shares0Common StockSEC:0000950170-24-074862:0
19,650 shares0Common StockSEC:0000950170-24-074873:0
19,650 shares0Common StockSEC:0000950170-24-074864:0
19,650 shares0Common StockSEC:0000950170-24-074875:0
19,650 shares0Common StockSEC:0000950170-24-074872:0
19,650 shares0Common StockSEC:0000950170-24-074865:0
185,000 shares0Common StockSEC:0000950170-24-041039:0
80,743 shares0Common StockSEC:0000950170-24-024920:0
80,743 shares0Common StockSEC:0000950170-24-024986:0
80,743 shares0Common StockSEC:0000950170-24-024921:0
25 of 83 declarations
About Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. (ticker: PSTX) is a United States biotechnology company that was listed on the NASDAQ and operated as a clinical-stage cell and gene therapy developer. Founded in 2014 through a corporate reorganization and spinout from Transposagen Biopharmaceuticals, Poseida built its business around proprietary non-viral gene engineering platforms and established its headquarters in San Diego, California, a major U.S. biotech hub. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm?utm_source=openai))
From an operating standpoint, Poseida focused on developing therapies for areas of high unmet medical need, especially hematologic cancers, with additional work spanning solid tumors, rare diseases, and more recently autoimmune-related programs in its broader pipeline communications. Its core technology stack centered on three differentiated platforms: the piggyBac non-viral DNA delivery system, the Cas-CLOVER site-specific gene editing platform, and nanoparticle- and AAV-based delivery technologies. These capabilities positioned the company as a specialist in both allogeneic cell therapy and in vivo genetic medicine. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm?utm_source=openai))
Read moreShow less
In competitive terms, Poseida was best known for pursuing off-the-shelf allogeneic CAR-T therapies, with a strong scientific emphasis on stem cell memory T cells (TSCM). That approach was intended to support better durability, potency, and safety relative to some earlier-generation cell therapy concepts. In 2024, the company highlighted progress around P-BCMA-ALLO1 for multiple myeloma and presented preclinical and early clinical updates across its broader cell-therapy pipeline. It also benefited from strategic collaborations with Roche and Takeda, which validated the platform while helping share development risk. ([poseida.com](https://poseida.com/news/poseida-therapeutics-highlights-positive-interim-phase-1-results-for-p-bcma-allo1-and-preclinical-data-for-dual-car-t-p-cd19cd20-allo1-at-the-66th-american-society-of-hematology-ash-annual-meeting/?utm_source=openai))
The most important recent development was Roche’s agreement in late 2024 to acquire Poseida, followed by the tender offer process and acceptance of tendered shares in early January 2025. Roche said the acquisition built on an existing collaboration in allogeneic CAR-T therapies. For investors, that means PSTX is no longer best viewed as a standalone public biotech story; instead, its value proposition became tied to Roche’s ownership, the closing mechanics, and any contingent value rights rather than to a conventional public-market growth narrative. ([roche.com](https://www.roche.com/investors/updates/inv-update-2024-11-26b?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
